Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an update.
C-RAD has appointed Tomas Blomquist as its new CEO, effective 2 February 2026, bringing in an international life science and medtech executive with more than 30 years’ experience, including a recent five-year tenure as CEO of Biotage and senior commercial roles at Abbott, Alere, Analyticon Biotechnologies and Johnson & Johnson. The leadership change sees acting CEO and CFO Linda Frölén return to her CFO role and the end of board member Peter Simonsbacka’s consulting assignment, with the board positioning Blomquist’s track record in building profitable growth and leading transformations as key to unlocking C-RAD’s strategic potential and shareholder value in the high-growth cancer care segment.
The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.
More about C-Rad AB Class B
C-RAD AB is a Sweden-based medtech company that develops surface-guided imaging solutions for radiation therapy, using high-speed 3D cameras and augmented reality to improve the accuracy of dose delivery to tumors while minimizing exposure to healthy tissue. Its technology supports precise patient setup and real-time motion monitoring without tattoos or additional imaging dose, aiming to enhance safety, comfort and workflow efficiency in cancer care. The company is listed on Nasdaq Stockholm.
YTD Price Performance: -0.47%
Average Trading Volume: 35,392
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.07B
Find detailed analytics on CRAD.B stock on TipRanks’ Stock Analysis page.